GSK entered a definitive agreement May 31 to purchase Affinivax, a clinical-stage, Boston-based biopharmaceutical company, for $2.1 billion and up to $1.2 billion in potential development milestones.
Read the full post on Becker's Hospital Review - Healthcare News
